NDA 018655 · Pfizer
Norpace Cr
Disopyramide Phosphate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: May 17, 2000 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
Jul 20, 1982
Approved uses
3
Original approval plus efficacy supplements
Registered trials
5
2 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 3, 1991 Supplement 26 · Efficacy
- Jun 19, 1985 Supplement 8 · Efficacy
- Jul 20, 1982 Original approval · Type 3 - New Dosage Form
2 products under this application
- NORPACE CR · DISOPYRAMIDE PHOSPHATE EQ 100MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
- NORPACE CR · DISOPYRAMIDE PHOSPHATE EQ 150MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Disopyramide" as an intervention, any sponsor and status, largest first.
- Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)Pivotal-lookingStatus unknown
Uppsala University HospitalAcademic, hospital or other
NCT02294955 · 152 participants · Start May 2008 · Primary completion Sep 2018
Drug: Amiodarone; Sotalol and 4 more · For: Atrial Fibrillation; Quality of Life
Sites: Uppsala, Sweden
CytokineticsIndustry
NCT04219826 · 96 participants · Start Jan 10, 2020 · Primary completion Feb 28, 2023
Drug: CK-3773274 (5 - 15 mg); CK-3773274 (10 - 30 mg) and 1 more · For: Hypertrophic Cardiomyopathy (HCM)
Sites: Los Angeles, California; San Francisco, California; Evanston, Illinois · 22 sites in all
- AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot StudyPivotal-lookingTerminated
Mayo ClinicAcademic, hospital or other
NCT00589303 · 27 participants · Start Dec 2007 · Primary completion Jul 2011
Drug: FDA approved rate and rhythm control drugs · For: Atrial Fibrillation; Heart Failure
Sites: Scottsdale, Arizona; Evansville, Indiana; Rochester, Minnesota · 6 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05556343 · 18 participants · Start Jan 18, 2023 · Primary completion Aug 19, 2024
Drug: MYK-224 · For: Cardiomyopathy, Hypertrophic
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 25 sites in all
- Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000556 · Start Mar 1995
Drug: amiodarone; sotalol and 10 more · For: Arrhythmia; Atrial Fibrillation; Cardiovascular Diseases and 1 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Norpace Cr (Disopyramide Phosphate)
2024 spending
$1.1M
Beneficiaries
408
1,640 claims
Per beneficiary
$2,757
$4.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,573,710 |
| 2021 | $159,720 |
| 2022 | $671,757 |
| 2023 | $812,958 |
| 2024 | $1,124,882 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Incidence, recurrence and management of electrical storm in Brugada syndrome.
El-Battrawy I, Roterberg G, Kowitz J, et al. · Front Cardiovasc Med 2022 · Systematic Review
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C, Valembois L, Bergmann JF, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Valembois L, Audureau E, Takeda A, et al. · Cochrane Database Syst Rev 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration.
Pollick C · Am J Cardiol 1988 · Clinical Trial, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.